Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. (Q47316489)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218622%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

review article

1 reference

title

Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218622%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

author

Smruthi Vijayaraghavan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218622%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

Stacy Moulder

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218622%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

Khandan Keyomarsi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218622%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

author name string

Rachel M Layman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218622%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

publication date

1 February 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218622%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218622%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218622%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218622%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

page(s)

21-38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218622%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11523-017-0541-2

6 April 2020

exact match

0 references

cites work

A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Treating cancer with selective CDK4/6 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

A CDK4/6-Dependent Epigenetic Mechanism Protects Cancer Cells from PML-induced Senescence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

The history and future of targeting cyclin-dependent kinases in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Targeting CDK4 and CDK6: From Discovery to Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Palbociclib and Letrozole in Advanced Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

New Approaches to Endocrine Therapy for Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Targeting cell cycle and hormone receptor pathways in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

CDK4/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell cycle arrest.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Phase II study of flavopiridol in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-017-0541-2

Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis

21 January 2018

1 reference

12 December 2020

Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

1 reference

12 December 2020

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

1 reference

12 December 2020

Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo.

1 reference

12 December 2020

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO)

1 reference

12 December 2020

Tamoxifen enhances the anti-proliferative effect of roscovitine, a selective cyclin-dependent kinase inhibitor, on human ER-positive human breast cancer cells.

1 reference

12 December 2020

Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer

1 reference

12 December 2020

Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity

1 reference

12 December 2020

10.1007/S11523-017-0541-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29218622%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

1 reference